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Introduction
Several epidemiological studies have demonstrated an inverse relationship between plasma high-density lipoprotein (HDL) and coronary heart disease, the major cause of morbidity and mortality in industrialized countries 1 . Apolipoprotein AI (apoAI) is the main HDL protein and its increased synthesis in producing HDL particles is an important intrinsic factor that reduces atherosclerotic risk. 1, 2 The key anti-atherogenic function of apoAI is the sequestration of excess cholesterol from peripheral cells for transfer to the liver for excretion, a process termed reverse cholesterol transport (RCT). 3 Thus, purified lipid-free apoAI mediates net efflux of cholesterol from several cell types, 4, 5 while overexpression of human apoAI protects mice from atherosclerosis induced by diet, 6 by apoE deficiency 7 or by the human apolipoprotein (a) transgene. 8 The cholesterol extracted from extra-hepatic cells by apoAI-containing HDL is esterified by lecithin-cholesterol acyltransferase (LCAT), the rate-limiting enzyme for HDL maturation which uses apoAI as cofactor. 2, 9 By con-verting diffusible cholesterol to insoluble cholesteryl ester LCAT drives RCT, and in LCAT transgenic mice the rate of cellular cholesterol efflux and transport of cholesteryl esters to the liver are increased. 10 Moreover, although infusion of apoAI alone can inhibit atherosclerosis in cholesterol-fed rabbits, 11 the net efflux of cholesterol from aortas is synergistically enhanced by LCAT. 12 Recombinant gene constructs based on adeno-associated virus (AAV) are attractive vectors for gene delivery, both in vitro and in vivo. They are nonpathogenic in humans, have a wide host cell range, can transduce nondividing cells and are integrated or retained in target cells. 13 On the other hand, nonviral delivery systems such as cationic liposomes [14] [15] [16] [17] and direct injection of plasmid vectors into skeletal muscle [18] [19] [20] are also established and offer safety and simplicity. Recently, Baudard et al 21 proposed liposome vehicles for transfection of AAV-based plasmid vectors; this combination overcomes their individual disadvantages, including the package size limit of AAV vectors and the transient nature of transfections using conventional liposome-mediated plasmid vectors. Furthermore, direct injection of AAV plasmids into skeletal muscle has been shown to produce long-term transgene expression. 22 Our long-term aim is to develop a safe and viable approach for prevention and treatment of atherosclerosis using heterologous gene augmentation of the HDL-asso-ciated proteins, apoAI and LCAT. Increasing evidence suggests that skeletal muscle may serve as a secretory platform for systemic gene expression. [23] [24] [25] Moreover, although LCAT and apoAI are mainly secreted into the circulation by hepatocytes, the direct injection of plasmid vector into skeletal muscle for permanent systemic delivery of therapeutic proteins may be more advantageous than viral-transduction of hepatocytes. [22] [23] [24] [25] Here, we have designed conventional and AAV-based plasmid vectors containing apoAI or LCAT cDNA, or both, and transfected these as lipoplexes into mouse C2C12 muscle cells or human 293 cells as a preliminary evaluation of their efficacy for delivery of apoAI and LCAT protein.
Results
Construction and characterisation of AAV-based plasmid expression vectors All recombinant AAV-based plasmid vectors were constructed from pNTC3CMV␤, in which a CMV-LacZ cassette from pCMV␤ was flanked by the 5Ј-and 3Ј-ITRs from AAV-2. 26 NotI digestion of pNTC3CMV␤ deleted the lacZ gene and allowed insertion of apoAI cDNA (806 bp) 27 or LCAT cDNA (1322 bp), 28 keeping the CMV immediate-early promotor SV40 splice donor/acceptor and SV40 polyA signal flanking the inserted sequences ( Figure 1 ). To coexpress apoAI and LCAT, an AAV-based bicistronic vector was produced by inserting intervening internal ribosome entry site (IRES) sequences derived from poliovirus ( Figure 1 ). IRES sequences promote ribosome binding and permit effective initiation of translation at internal sites within a mRNA. 29 Therefore, when two different genes are linked by the IRES sequence within a plasmid, both genes are transcribed as a single mRNA driven by the same promoter but are translated independently. Control plasmids lacking AAV sequence elements were constructed in a parallel manner but based on the original pCMV␤ plasmid by deletion of the lacZ sequences and replacement with apoAI and LCAT cDNAs.
Expression and secretion of recombinant apoAI by C2C12 and 293 cells To determine whether cells transfected with pCMVAI and pNTC3CMVAI would synthesize and secrete human apoAI, cultures of the mouse myoblast cell line C2C12 and human 293 cells were transfected with plasmid vectors complexed to lipofectamine. As detailed in Materials and methods, serum-free medium samples were collected over the periods of 24-48, 48-72 and 72-96 h after transfection. The concentrations of released human apoAI were then measured by ELISA. Cells transfected with both the AAV-and non-AAV-based vectors expressed significant levels of human apoAI at all three time-points (Table 1) , with the yield from 293 cultures being generally greater than from C2C12 cells. Western blot analyses of medium samples confirmed that the released immunoreactive recombinant apoAI protein was of identical M r to authentic human plasma apoAI (Figure 2) . Importantly, the expression efficiency with the AAV-based plasmid vector (pNTC3CMVAI) was significantly better (two-to five-fold; up to 2.3 g/ml) than with pCMVAI and there was no evidence of decreased production with time (Table 1) .
Expression and secretion of recombinant LCAT by C2C12 and 293 cells
The same protocol was adopted to establish whether cells transfected with pCMVLCAT or pNTC3CMVLCAT could secrete functional LCAT, using the proteoliposome method 30, 31 to measure LCAT catalytic activity (Table 2 ) and Western blotting to detect released protein ( Figure  3 ). The findings were similar to those obtained using the apoAI expression vectors. Thus, the AAV-based plasmid vector, pNTC3CMVLCAT, clearly expressed more LCAT (two-to five-fold; Table 2 ) of the correct predicted size ( Figure 3 ) than pCMVLCAT without a time-dependent fall in production. The yield from 293 cells was two to five times (up to 6 g/ml) that from the C2C12 muscle cells.
Simultaneous expression of apoAI and LCAT When C2C12 and 293 cells were transfected with the AAV-based bicistronic plasmid vector, pNTC3CMVAIL, both apoAI and LCAT were secreted into the culture media ( Table 3 ). The amounts of protein accumulating were significantly lower than those achieved with the corresponding singly-expressing cDNA plasmids (Tables  1 and 2 ), but as with the individual AAV-based plasmid vectors, there was no evidence of reduced synthesis with time; indeed, the apparent yield of LCAT increased steadily, perhaps because simultaneous secretion of its cofactor, apoAI helped stabilize the enzyme.
2,9
Retention of vector sequences by transfected cells One desirable characteristic of AAV-based vectors is persistence in host cells as integrated or unintegrated cop- ies. 32 To assess retention of our conventional and AAVbased plasmid vector sequences in transfected C2C12 myoblasts, genomic DNA was extracted for PCR analysis from cultures 14 days after transfection which had been maintained through two passages. As a negative control, DNA of nontransfected C2C12 cells was included. For positive controls, pLNPOZ plasmid DNA was used as a PCR template to amplify poliovirus IRES, and pCMVAI plasmid DNA as a template for the apoAI cDNA; preliminary experiments confirmed that both primer pairs amplified the predicted sequences in DNA from pLNPOZ or pCMVAI, respectively, but gave no products with control nontransfected C2C12 genomic DNA. As indicated in Figure 4 , after the 14 day period, the full apoAI cDNA sequence was present in C2C12 cultures which had been transfected by the AAV-based plasmid pNTC3CMVAI, whereas none were detected in cells
Figure 4 Prolonged AAV plasmid vector retention in transfected C2C12 cell cultures. Control untransfected C2C12 cells (lane 1), and cells transfected with pNTC3CMVAIL, pNTCCMVAI or pCMVAI (lanes 2, 3 and 4, respectively) were maintained in culture for 14 days and total nuclear DNA isolated. DNA samples were then probed by PCR amplification of the apoAI cDNA sequence (a, 821 bp band) or the polio virus IRES (b, 793 bp band). Lanes 5 and 6 show control amplifications using plasmid DNA templates, pCMVAI and pLNPOZ, respectively.
transfected by the conventional non-AAV-based plasmid pCMVAI. Furthermore, in 14 day cultures transfected with the AAV plasmid pNTC3CMVAIL both apoAI cDNA, poliovirus IRES ( Figure 4 ) and LCAT sequences (not shown) could be amplified indicating that the bicistronic gene remained intact.
Discussion
The present studies demonstrate that mouse C2C12 muscle cells or 293 cells transfected with conventional or AAV-based plasmid vectors containing human apoAI or LCAT cDNAs efficiently synthesize and secrete the corresponding proteins, and that the AAV-based bicistronic vector, pNTC3CMVAIL, coexpresses apoAI and LCAT. Furthermore, transgene sequences of AAV-based vectors exhibited significantly enhanced expression and nuclear retention characteristics compared with conventional plasmid vectors. In the latter case, the PCR-based analyses provide qualitative evidence, but Southern blotting will be required to quantify the level and nature of the retained transgene elements.
Recombinant adeno-associated viruses are attractive reagents for gene therapy as they stably transduce nondividing cells at high efficiency both in vitro and in vivo. [33] [34] [35] [36] However, the package size limits of the AAV virion and the current inefficiency of rAAV production and purification, 23 as well as safety considerations, continue to restrict the clinical use of this gene delivery system. In addition, AAV particle administration may induce a humoral immune response against AAV capsid proteins, thereby limiting the gene transfer efficiency of a second vector administration. 37 To overcome these problems, liposomes have recently been proposed as vehicles to deliver the DNA of AAVbased vectors. 21 Although liposomes are accepted as clinically useful nonviral reagents for gene transfer of plasmids, expression of the transgene is usually transient because the transfected plasmid is lost during division of the host cell. However, the combination of liposomes and AAV-based plasmid vectors has clear advantages; liposome-mediated transfection avoids the size limitation of AAV, eliminates the preparation of virus and circumvents the immune response evoked by AAV capsid proteins. In addition, the inverted terminal repeat sequences (ITRs) of AAV potentially facilitate entry and retention of the transfected plasmid DNA in target cell nuclei, and may allow vector integration into genomic DNA. Such nuclear accumulation of the transfected AAV plasmid DNA should enhance both the level and persistence of expression as demonstrated in vitro 38 and in vivo. 21 Our findings provide important support for use of this combination gene delivery system. Transgene expression levels of cells transfected with liposome-AAV-based plasmid vector complexes (pNTC3CMVAI and pNTC3CM VLCAT) were two to four times higher than those of cells receiving liposome-pCMVAI/LCAT, while genomic DNA analysis 14 days after transfection indicated significant retention of AAV-based plasmid vector DNA, but not pCMV DNA, by the host cell nucleus. ApoAI is a major contributor to the anti-atherogenic actions of HDL because of its multiple roles in RCT; it avidly accepts cellular cholesterol, 3, 5 acts as a ligand for HDL receptors, 39, 40 and is a cofactor for LCAT. 41, 42 As LCAT also regulates HDL levels and is important for effective RCT, 9,10 both of these plasma proteins have emerged as attractive candidate targets for sustained systemic delivery in order to prevent or treat atherosclerosis. Their effectiveness has been confirmed in experimental animals, using transgenic mice 43, 44 and rabbits 45, 46 overexpressing apoAI or LCAT, or by transient hepatic gene expression using adenovirus vectors. 47, 48 Our own work is focussed towards skeletal muscle as a secretory platform for systemic gene expression using direct injection of plasmid vectors; this has advantages over infection of virus into liver in terms of safety, cost and convenience. Our present results support the concept that liposome-AAV-based plasmid vectors will allow persistent expression of anti-atherogenic apoAI and LCAT from muscle, either individually or simultaneously by use of the biscistronic vector, pNTC3CMVAIL. Clearly, further investigations of this strategy and of testing vector efficacy will require detailed studies in vivo and the use of pre-clinical models of atherosclerosis.
Materials and methods
Generation of conventional plasmid vectors and AAVbased plasmid vectors An LCAT cDNA (1322 bp) corresponding to the published sequence 28 and spanning the entire coding region for pre-pro-apoAI was a gift from Dr John McLean (Genentech, San Francisco, CA, USA). ApoAI cDNA (806 bp) corresponding to the published sequence 27 was prepared by PCR amplification from a human liver cDNA sample kindly supplied by Dr David Booth (Royal Postgraduate Medical School, Hammersmith Hospital, London, UK). Conventional, non-AAV, expression plasmids were constructed using pCMV〉 (Clontech, Palo Alto, CA, USA) as the base. The lacZ gene was excised from pCMV␤ by NotI digestion, and LCAT and apoAI cDNAs were blunt-end ligated into the filled site to generate pCMVLCAT and pCMVAI, respectively.
All AAV-based plasmid vectors were constructed from plasmids based upon pNTC3/M1 and pNTC3CMV␤ (a kind gift of Dr Sam Wadsworth and Susan Piraino, Genzyme Corporation, Framingham, MA, USA). pNTC3/M1 has a pTZ19U backbone containing the entire genome of AAV-2 from pAV2 cloned at the BamHI site. 26 An EcoRISalI fragment containing the CMV/LacZ/SVpA cassette from pCMV␤ was then cloned into EcoRV and SnaBIdigested pNTC3/M1 to yield pNTC3CMV␤. As described above in the case of pCMV␤, the NotI fragment of pNTC3CMV spanning the lacZ gene was removed and replaced with LCAT or apoAI cDNAs by blunt-end ligation to form pNTC3CMVLCAT or pNTC3CMVAI, respectively (see Figure 1) . The bicistronic AAV-based plasmid vector pNTC3CMVAIL (see Figure 1 ) was constructed in several steps: (1) cloning of LCAT cDNA into the BamHI and XbaI sites of pUC19 to yield pUCLCATr; (2) generation of an IRES sequence of poliovirus by PCR amplification using pLNPOZ 49 as template (sense primer 5Ј-CGGAATTCTGATATCTTAAAACAGCTCTG GGGTTGT-3Ј; antisense primer 5Ј-CTCCCCCGGGCC CGGATCCGCAGATCAGCTTTT-3Ј); (3) insertion of the IRES fragment into the EcoRI and XmaI sites of pUCLCATr upstream of the LCAT cDNA to generate pIRESLCAT; (4) blunt-end insertion of the apoAI cDNA into the EcoRV site of pIRESLCAT upstream of the IRES sequence to generate pAIL containing the bicistronic apoAI cDNA-IRES-LCAT cDNA fragment; and (5) removal of the lacZ gene from pNTC3CMV␤ by digestion with NotI and its replacement with the apoAI cDNA-IRES-LCAT cDNA fragment from pAIL by blunt-end ligation to generate bicistronic AAV-based plasmid vector, pNTC3CMVAIL (Figure 1 ).
Culture and transfection of 293 and C2C12 cells
Human embryonic kidney 293 cells and murine C2C12 myoblast cells were grown at 37°C as adherent monolayers in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated FCS. For gene transfer and expression studies, multiwells (40 mm) were seeded with 2 × 10 5 C2C12 or 1.5 × 10 6 293 cells and 24 h later transfected with plasmid lipoplexes prepared with lipofectamine (GIBCO-Life Technologies, Paisley, UK) as previously described. 15, 16 Cells were maintained in DMEM with 10% FCS (293 cells) or 5% heat-inactivated horse serum (HS: C2C12 cells), and then switched to serum-free DMEM at 24, 48 or 72 h following transfection. Under these conditions C2C12 myoblasts are induced to differentiate into multinucleate myotubes over the first 24-48 h. Serum-free medium samples were then removed after a further 24 h incubation, and analysed for accumulation of secreted apoAI or LCAT. No differential effects of control or AAV-based plasmids on cell number or morphology were observed over the course of these studies, and at early time-points, lacZ reporter plasmids, pCMV␤ and pNTC3CMV␤, yielded similar transfections efficiencies.
Genomic DNA analysis by the polymerase chain reaction Total genomic DNA of transduced 293 or C2 cells was extracted 50 and subjected to PCR analysis. The presence of the poliovirus IRES sequence was examined with the primer-pair (5Ј-CGGAATTCTGATATCTTAAAACAG CTCTGGGGTTGT-3Ј and 5Ј-CTCCCCCGGGCCCGGA TCCGCAGATCAGCTTTT-3Ј) to amplify a 793-bp fragment, while detection of the apoAI cDNA sequence used the primers (5Ј-CTTGAATCCACCATGAAAGCTGC GGTGCTGACC-3Ј and 5Ј-CTTAAGCTTTCACTGGG TGTTGAGCTTCTTAGT-3Ј) to amplify an 821-bp fragment. Both amplifications were conducted for 30 cycles (95°C for 0.5 min, 55°C for 1.5 min and 72°C for 2 min). The PCR products were analysed by electrophoresis on 1% agarose gel in the presence of ethidium bromide.
Measurement of human apoAI
Secretion of human apoAI into the culture medium of transduced cells was monitored using a standard two-antibody sandwich ELISA. A mouse monoclonal antibody (Clone 3-F10, Isotype IgG 2a ) was used for capture and affinity-purified goat polyclonal antibody for detection (PerImmune, Rockville, MD, USA); horseradish peroxidase-conjugated rabbit anti-goat IgG and O-phenylenediamine (both Sigma, Poole, UK) were used for colour development and purified human plasma apoAI was the standard (PerImmune).
Measurement of LCAT activity
The LCAT catalytic activity in serum-free media was determined by our established protocol 31 using 3 H cholesterol-labelled proteoliposomes as substrate. Results were initially calculated as the percentage of cholesterol esterified per h/ml culture media and corrected for reagent blanks. A control pool of normal plasma was included in each assay and, assuming a content of 6 g LCAT/ml, was used to estimate the mass of LCAT secreted into the media. 30, 51, 52 Western blotting Culture media containing secreted human apoAI or LCAT were concentrated 10-fold by ultrafiltration (VIVASPIN, 10,000 MWCO; Vivascience, Lincoln, UK). Test samples and standards (purified human apoAI (PerImmune) and recombinant LCAT 52 ) were separated by 10% SDS-PAGE and transferred on to polyvinylidene fluoride (PVDF) membranes (0.2 m, Bio-Rad, Hemel Hempstead, UK). After blocking with 10% fat-free milk powder at 4°C overnight, the blots were incubated with primary antibodies (rabbit anti-human apoAI (PerImmune) and an in-house rabbit anti-human LCAT polyclonal antibody 53 ) at room temperature for 2 h and washed with 100 mm Tris buffer (pH 8.0) containing 0.05% Tween 20. Detection was by chemiluminescence using a commercial ECL Western blotting kit (Amersham, High Wycombe, UK).
